A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: The Pentasaccharide in Unstable Angina (PENTUA) study

Journal of the American College of Cardiology

Volumn 43, Issue 12, 2004, Pages 2183-2190

  Simoons, Maarten L ^a   Bobbink, Inge W G ^b   Boland, Jean ^c   Gardien, Martin ^a   Klootwijk, Peter ^a   Lensing, Anthonie W A ^b,d   Ruzyllo, Witold ^e   Umans, Victor A W M ^f   Vahanian, Alec ^g   Van De Werf, Frans ^h   Zeymer, Uwe ⁱ  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NV ORGANON   (Netherlands)

^c CHR Citadelle ^*  (Belgium)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e INSTITUTE OF CARDIOLOGY   (Poland)

^f Location Alkmaar   (Netherlands)

^g BICHAT HOSPITAL   (France)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ KLINIKUM KASSEL   (Germany)

Author keywords

ACS; acute coronary syndromes; CABG; CK MB; coronary artery bypass graft surgery; creatine kinase MB fraction; ECG; electrocardiographic; LMWH; low molecular weight heparin; MI; myocardial infarction; PCI; PENTUA; percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; PENTASACCHARIDE;

ADULT; ARTICLE; BLEEDING; BLOOD TOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CORONARY ARTERY BYPASS; CORONARY DISEASE; CREATINE KINASE; CREATINE KINASE, MB FORM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; POLYSACCHARIDES; SURVIVAL ANALYSIS; SYNDROME; TREATMENT OUTCOME; TROPONIN T;

EID: 2942582865     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.02.051     Document Type: Article

References (26)

1. Bertrand M.E., Simoons M.L., Fox K.A.A., et al. Management of acute coronary syndromes Acute coronary syndromes without persistent ST-segment elevation. recommendations of the Task Force of the European Society of Cardiology. Eur Heart J. 23:2002;1809-1840
2. Boersma E., Harrington R.A., Moliterno D.J., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes A meta-analysis of all major randomised clinical trials. Lancet. 19:2002;189-198
3. Bauer K.A. Fondaparinux sodium A selective inhibitor of factor Xa. Am J Health Syst Pharm. 58:(Suppl 2):2001;S14-S17
4. Pentasaccharide Investigators, Turpie A.G.G., Gallus A.S., Hoek J.A. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 344:2001;619-625
5. Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study, Eriksson B.I., Bauer K.A., Lassen M.R., et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 345:2001;1298-1304
6. Steering Committee of the Pentasaccharide in Major Knee Surgery Study, Bauer K.A., Eriksson B.I., Lassen M.R., et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 345:2001;1305-1310
7. PENTATHLON 2000 Study Steering Committee, Turpie A.G.G., Bauer K.A., Eriksson B.I., et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery A randomised double-blind trial. Lancet. 359:2002;1721-1726
8. European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee, Lassen M.L., Bauer K.A., Eriksson B.I., et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery A randomised double-blind comparison. Lancet. 359:2002;1715-1720
9. Coussement P.K., Bassand J.P., Convens C., et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction The PENTALYSE study. Eur Heart J. 22:2001;1716-1724
10. Klootwijk P., Meij S., Melkert R., et al. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Circulation. 98:1998;1358-1364
11. Akkerhuis K.M., Klootwijk P.A., Lindeboom W., et al. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events Metaanalysis of three studies involving 995 patients. Eur Heart J. 22:2001;1997-2006
12. The Thrombolysis In Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina Results of TIMI 11A. J Am Coll Cardiol. 29:1997;1474-1482
13. Cohen M., Demers C., Gurfunkel E.P., et al. Comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 337:1997;447-452
14. Antman E.M., McGabe C.H., Gurfunkil E.P., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation. 12:1999;1593-1601
15. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J. 2121:2000;1502-1513
16. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary disease. Lancet. 336:1990;827-830
17. Theroux P., Ouimet H., McCans J., et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 319:1988;1105-1111
18. The FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery disease FRagmin during InStability in Coronary artery disease. Lancet. 347:1996;561-568
19. Eikelboom J.W., Anand S.S., Malmberg K., et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation A meta-analysis. Lancet. 355:2000;1936-1942
20. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 345:2001;494-502
21. Bounaneaux H., Perneger T. Fondaparinux A new synthetic pentasaccharide for thrombosis prevention: a commentary. Lancet. 359:2002;1710-1711
22. Sheldon T. How whistleblowing cost one doctor 550000 pounds. BMJ. 324:2002;1240
23. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRIMS-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIA receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 338:1998;1488-1497
24. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIA with eptifibatide in patients with acute coronary syndromes. N Eng J Med. 339:1998;436-443
25. GUSTO IV-ACS Investigators, Simoons M.L. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization The GUSTO IV-ACS randomised trial. Lancet. 357:2001;1915-1925
26. Leebeek F.W.G., Boersma E., Cannon C.P., van de Werf F.J., Simoons M.L. Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease Why were the results so unfavourable? Eur Heart J. 23:2002;444-457